BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics, Inc. is a NASDAQ-listed common equity security representing a biopharmaceutical company focused on applying artificial intelligence methods to drug development in neuroscience and immuno-oncology. Through the company and its subsidiary, OnkosXcel Therapeutics LLC, the business develops and commercializes therapies for serious medical conditions in the United States. Its marketed product includes IGALMI, a sublingual film approved for the acute treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults. The company also advances a pipeline of investigational programs, including BXCL501 for multiple neuropsychiatric and substance-use related indications, BXCL701 for certain cancers, and additional candidates BXCL502, BXCL503, and BXCL504 in dementia-related and stress-related disorders. BioXcel Therapeutics was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BTAI
|
$0.97
|
8.6% Upside
|
Fair
|
$14 1,469.5% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-0.4x
|
-0.3x
|
40.9x
|
27.253 M
|
110.9 M
|
78.6%
|
85.4%
|
-35.6
|
—
|
76.2%
|
